Overall numbers solid and in line with forecasts. Pharma division strength covering for the smaller Diagnostics weakness. Outlook confirmed.
• Sales CHF 30,944m +7% cc.
• Core Op Profit CHF12bn +11% cc. Net Income CHF 7.8bn +23%.
• Pharma CHF 23bn +10%; Diagnostics CHF 6.96bn flat with continued Chinese weakness.
• New pharma drivers offsetting loss-of-exclusivity is a real positive.
• 15.2% growth combined for Phesgo, Xolair, Hemlibra, Vabysmo and Ocrevus. Total of CHF 10.6bn up from 9.2bn.
Find more articles and bullets on these widgets:
The trend condition in BTP futures is unchanged, it remains bullish and the latest pullback appears corrective. Recent gains reinforce a bull theme and maintain the price sequence of higher highs and higher lows. Sights are on the 122.00 handle next. Key support to watch lies at 118.51, the May 14 low. A clear break of this level would highlight a reversal. First support is 119.91, the May 29 low.
Slovenia will hold a syndication in the near future while Germany and Italy are both still scheduled to hold conventional auctions this week and Finland is due to hold an ORI auction. The EU and Belgium have already held auctions this week. We pencil in estimated gross issuance for the week of E28.7bln, a little lower than the E30.7bln last week.
EURGBP continues to trade at its recent highs and a bullish theme remains intact. The recent breach of the 50-day EMA highlighted a stronger reversal. This signals scope for an extension towards 0.8592 next, a Fibonacci retracement. On the downside, support to watch lies at 0.8469, the 50-day EMA. Clearance of this level would instead highlight a possible reversal. Support at the 20-day EMA is at 0.8495.